跳至主要内容
临床试验/KCT0001259
KCT0001259已完成未知

Effects of acupuncture for prehypertension & stage 1 hypertension in postmenopausal women : a multi-center, randomized, controlled trial

Korea Institute of Oriental Medicine0 个研究点目标入组 56 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
56

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
45(Year) 至 65(Year)(—)
性别
Female

入选标准

  • 1. Women aged 45 to 65 years
  • 2. Menstruation ended 1 year or longer prior to the study
  • 3. Resting blood pressure measured during screening is in the prehypertension stage (systolic blood pressure (SBP) of 120–139 mmHg or diastolic blood pressure (DBP) of 80–89 mmHg) or at stage 1 hypertension (SBP of 140–159 mmHg or DBP of 90–99 mmHg)
  • 4. Provide consent to participate in this trial and sign an informed consent statement after listening to a clear explanation of the purpose and characteristics of this clinical trial

排除标准

  • 1. Received antihypertensive drugs, herbal medication or functional food used for hypertension, herbal tea such as persimmon leaf tea within the past 1 months
  • 2. Received hormone therapy, such as estrogen or progestin, herbal medication or functional food used for involutional disorder in the past 1 month
  • 3. History of secondary hypertension or are suspected of secondary hypertension (for example, coarctation of the aorta, renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing’s syndrome, polycystic renal disease, hyperthyroidism
  • 4. Orthostatic hypotension and accompanying symptoms
  • 5. Uncontrolled diabetes mellitus
  • 6. Severe heart disease, ischemic heart disease during the recent 6 months (angina pectoris, myocardial infarction), or peripheral vascular disease, or have received percutaneous transluminal coronary angioplasty or a coronary artery bypass graft
  • 7. Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortostenosis, or hemodynamically significant aortic or mitral valve stricture
  • 8. Severe cerebrovascular disease, or have experienced a cerebral infarction or cerebral hemorrhage within the past 6 months
  • 9. Moderate or malignant retinosis, retinal hemorrhage, visual disturbance, or retinal microaneurysm within the past 6 months
  • 10. Consumptive disease (tuberculosis, malignant tumors) or autoimmune disease (systemic lupus erythematosus, rheumatoid arthritis, dermatomyositis, systemic sclerosis, or thyroiditis)
  • 11. Clinically significant kidney or liver disease
  • 12. Confirmed or suspected history of drug or alcohol abuse
  • 13. Chronic inflammatory conditions that require chronic anti-inflammatory treatment
  • 14. Currently participating in other clinical trials
  • 15. Currently an inmate at a group facility, such as a social welfare institution
  • 16. Did not provide informed consent
  • 17. Anyone considered inappropriate for participating in this trial by the clinical trial conductors

研究者

相似试验